Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Markers of Kidney Tubular Secretion and Risk of Acute Kidney Injury after Acute Heart Failure.

Kidney360·2026
Same author

Markers of kidney tubule dysfunction and injury and long-term risk of acute kidney injury following coronary artery bypass graft surgery.

PloS one·2026
Same author

Estradiol protects kidney tubules against ferroptosis.

Kidney international·2026
Same author

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC.

Nature reviews. Clinical oncology·2026
Same author

Implementing virtual reality for emergency training in nephrology: a large-scale study on educational impact and acceptance.

Clinical kidney journal·2026
Same author

National Institutes of Health Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials.

Clinical journal of the American Society of Nephrology : CJASN·2026

Related Experiment Video

Updated: Apr 30, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K

Antifibrotic vitamin D analogs.

Joseph V Bonventre

    The Journal of Clinical Investigation
    |October 29, 2013
    PubMed
    Summary

    New vitamin D receptor ligands target fibrosis pathways to treat chronic kidney disease. These compounds reduced kidney fibrosis in mouse models, offering hope for human therapies.

    Area of Science:

    • Nephrology
    • Pharmacology
    • Molecular Biology

    Background:

    • Chronic kidney disease (CKD) is characterized by progressive kidney fibrosis, impairing renal function.
    • Effective treatments to mitigate renal fibrosis are urgently needed.
    • The transforming growth factor-beta (TGF-β)-SMAD signaling pathway is a key regulator of fibrosis-associated gene expression.

    Purpose of the Study:

    • To develop novel synthetic ligands for the vitamin D receptor (VDR).
    • To target the TGF-β-SMAD signaling pathway for reducing renal fibrosis.
    • To evaluate the efficacy of these ligands in ameliorating kidney fibrosis without activating VDR-associated genes.

    Main Methods:

    • Development of synthetic VDR ligands.
    • In vitro and in vivo studies assessing the impact on the TGF-β-SMAD pathway.

    More Related Videos

    Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
    07:13

    Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

    Published on: May 24, 2024

    1.1K
    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
    10:29

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

    Published on: May 9, 2025

    2.0K

    Related Experiment Videos

    Last Updated: Apr 30, 2026

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
    10:46

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

    Published on: December 9, 2015

    10.3K
    Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
    07:13

    Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

    Published on: May 24, 2024

    1.1K
    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
    10:29

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

    Published on: May 9, 2025

    2.0K
  • Evaluation of renal fibrosis in two distinct mouse models of kidney disease.

    • Main Results:

    • Synthetic VDR ligands were successfully developed.
    • These ligands effectively targeted the TGF-β-SMAD signaling pathway.
    • Significant amelioration of renal fibrosis was observed in treated mouse models.
    • Ligands did not induce known VDR-associated genes, suggesting a targeted therapeutic approach.

    Conclusions:

    • Novel synthetic VDR ligands show promise for treating renal fibrosis.
    • Targeting the TGF-β-SMAD pathway with these compounds is a viable therapeutic strategy.
    • Further investigation is warranted for potential human application in chronic kidney disease and other fibrotic disorders.